1-8 of 8
Bing Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist

Akinori Morita, Ippei Takahashi, Megumi Sasatani, Shin Aoki, Bing Wang, Shinya Ariyasu, Kaoru Tanaka, Tetsuji Yamaguchi, Akiko Sawa, Yurie Nishi, Tatsuro Teraoka, Shohei Ujita, Yosuke Kawate, Chihiro Yanagawa, Keiji Tanimoto, Atsushi Enomoto, Mitsuru Nenoi, Kenji Kamiya, Yasushi Nagata, Yoshio Hosoi, Toshiya Inaba
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (2): 432–442.
https://doi.org/10.1158/1535-7163.MCT-16-0554
Published: 01 February 2018
View article titled, A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
Open the PDF for A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist in another window
Includes: Supplementary data
Journal Articles

Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer

Jianguo Feng, Shirong Zhang, Kan Wu, Bing Wang, Jeffrey Y.C. Wong, Hong Jiang, Rujun Xu, Lisha Ying, Haixiu Huang, Xiaoliang Zheng, Xufeng Chen, Shenglin Ma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 842–853.
https://doi.org/10.1158/1535-7163.MCT-15-0445
Published: 05 May 2016
View article titled, Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Open the PDF for Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B93: Preclinical evaluation of BMN 673 in combination with temozolomide (TMZ) in various tumor types including small cell lung cancer (SCLC) cells.

Ying Feng, Leonard Post, Bing Wang, Yuqiao Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B93.
https://doi.org/10.1158/1535-7163.TARG-13-B93
Published: 01 November 2013
View article titled, Abstract B93: Preclinical evaluation of BMN 673 in combination with temozolomide (TMZ) in various tumor types including small cell lung cancer (SCLC) cells.
Journal Articles

Abstract B64: Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent.

Yuqiao Shen, Ying Feng, Bing Wang, Peter Myers, Daniel Chu, Leonard E. Post
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B64.
https://doi.org/10.1158/1535-7163.TARG-11-B64
Published: 12 November 2011
View article titled, Abstract B64: Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent.
Journal Articles

Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies

Bing Wang, Daniel Chu, Ying Feng, Xin Yu, Peter Myers, Leonard Post, Yuqiao (Jerry) Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A121.
https://doi.org/10.1158/1535-7163.TARG-09-A121
Published: 10 December 2009
View article titled, Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies
Journal Articles

CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo

Christopher J. Burns, Emmanuelle Fantino, Ian D. Phillips, Stephen Su, Michael F. Harte, Patricia E. Bukczynska, Mark Frazzetto, Max Joffe, Irma Kruszelnicki, Bing Wang, Yue Wang, Neil Wilson, Rodney J. Dilley, Soo S. Wan, Susan A. Charman, David M. Shackleford, Rosa Fida, Cathy Malcontenti-Wilson, Andrew F. Wilks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 3036–3045.
https://doi.org/10.1158/1535-7163.MCT-09-0076
Published: 10 November 2009
View article titled, CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity <em>in vitro</em> and <em>in vivo</em> in another window
Journal Articles

17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells

Shou-Sheng Yan, Ying Li, Ying Wang, Shen-Si Shen, Yuan Gu, Hong-Bing Wang, Guo-Wei Qin, Qiang Yu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (6): 1523–1532.
https://doi.org/10.1158/1535-7163.MCT-08-0263
Published: 19 June 2008
View article titled, 17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells
Open the PDF for 17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells in another window
Journal Articles

A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells

Tao Zhang, Adel Hamza, Xianhua Cao, Bing Wang, Shuwen Yu, Chang-Guo Zhan, Duxin Sun
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 162–170.
https://doi.org/10.1158/1535-7163.MCT-07-0484
Published: 17 January 2008
View article titled, A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Open the PDF for A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells in another window
Includes: Supplementary data